The GlaxoSmithKline (NYSE: GSK) cervical cancer candidate vaccine, CERVARIX®, demonstrated 100 percent efficacy in preventing precancerous lesions due to cancer-causing human papillomavirus types 16 and 18 for up to 5.5 years in an extended follow-up trial, according to data presented today at the American Association for Cancer Research. The trial results demonstrate the longest duration of protection seen in any cervical cancer vaccine trial reported to date.

Source: Cervarix® Offers 100% Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 And 18 For Over 5 Years


Post a Comment

Google Analytics Alternative